This is a working overview of Ipamorelin, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-22 and is reviewed periodically as new material appears.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
现有文献多来自小规模、短期的研究，涉及生长激素缺乏、术后肠麻痹等方向。长期使用是否导致受体脱敏，以及重复给药后效应是否衰减，仍属开放问题。不同研究之间的剂量、给药途径和受试者特征差异较大，因此结论外推需谨慎。关于临床获益的确切证据尚不充分，需要更大规模的对照试验来澄清。
Ipamorelin 是一种合成五肽，在 20 世纪 90 年代被报道为生长激素促分泌剂。其结构基于胃饥饿素受体激动剂的设计思路，但并非天然激素。早期药理学研究显示，它可刺激垂体释放生长激素，而对应激激素轴的影响相对较小。该化合物常被用作研究生长激素调节通路的工具分子。
在机制层面，ipamorelin 与生长激素促分泌受体 1a 型结合，该受体也介导胃饥饿素的多种效应。受体激活后，细胞内信号促进生长激素从垂体前叶释放。由于对促肾上腺皮质激素和皮质醇的刺激较弱，它被视为选择性较高的促分泌剂。这种选择性在动物模型和少量人体研究中被观察到，但人体数据仍然有限。
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Value for the free base |
| Molar mass | 711.9 g/mol | Calculated from the formula |
| Appearance | White to off-white powder | Typical lyophilized form |
| Mechanism class | Ghrelin receptor agonist | Also described as a secretagogue |
| Half-life | About 2 hours | Reported for human circulation |
Common solvents for laboratory work include water, buffered saline, and dimethyl sulfoxide. Once dissolved, the peptide is exposed to hydrolysis and oxidation, and alkaline conditions accelerate breakdown. Low-binding plasticware and the addition of a carrier protein reduce losses to container surfaces, which can otherwise be substantial at low concentrations. Solutions are typically kept cold and used within days. Investigators working with the compound generally prepare fresh working dilutions rather than storing dilute stocks, and they avoid repeated warming of the same vial.
Reversed-phase high-performance liquid chromatography is the standard method for purity assessment, most often on a C18 column with a water and acetonitrile gradient and trifluoroacetic acid or formic acid as an ion-pairing agent. Mass spectrometry by electrospray or matrix-assisted laser desorption confirms the expected mass and reveals truncated or modified sequences. Amino acid analysis and sequencing provide orthogonal structural evidence. Typical impurities include deletion sequences, oxidized products, and dimeric species. Detection wavelength, usually 214 or 220 nanometers, should be reported because response factors differ between peptides.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
The so-called Stele of the Vultures, now in the Louvre, is a fragmented limestone stele found in Telloh, (ancient Girsu) Iraq, in 1881. The stele is reconstructed as having been 1.8 metres (5 ft 11 in) high and 1.3 metres (4 ft 3 in) wide and was set up c. 2450 BCE. It was erected as a monument of the victory of Eannatum of Lagash over Ush, king of Umma, leading to a boundary treaty with his successor Enakalle of Umma. On it, various incidents in the war are represented. In one register, the king (his name appears inscribed around his head) stands in front of his phalanx of heavily armoured soldiers, with a curved weapon in his right hand, formed of three bars of metal bound together by rings. In another register a figure, the king, his name again inscribed around his head, rides on his chariot in the thick of the battle, while his kilted followers, with helmets on their heads and lances in their hands, march behind him. On the other side of the stele is an image of Ninurta, a god of war, holding the captive Ummaites in a large net. This implies that Eannatum attributed his victory to Ninurta, and thus that he was in the god's protection (though some accounts say that he attributed his victory to Enlil, the patron deity of Lagash). The victory of Eannatum is mentioned in a fragmentary inscription on the stele, suggesting that after the loss of 3,600 soldiers on the field, Ush, king of Umma, was killed in a rebellion in his capital city of Umma: “[…] (Eannatum) defeated him.
== External links == Works by or about Frederick Gowland Hopkins at the Internet Archive Frederick Gowland Hopkins on Nobelprize.org Frederick Gowland Hopkins at Find a Grave Biography by N.J.T. Thomas Chemical genealogy Frederick Gowland Hopkins[link removed]
=== Potential for toxicity === Preliminary research indicates that prolonged exposure to high doses of THC may interfere with chromosomal stability, which may be hereditary as a factor affecting cell instability and cancer risk. The carcinogenicity of THC in the studied populations of so-called "heavy users" remains dubious due to various confounding variables, most significantly concurrent tobacco use.
=== Bombing test === This method applies to objects that are supposedly hermetically sealed such as implantable medical devices, crystal oscillator, saw filter devices, transistors, microprocessors, etc. First the device under test will be exposed to helium pressure (typically 30-60psi) in a "bombing" chamber for an extended time period. If the part is leaky, helium will be able to penetrate the device. Later the device will be placed in a vacuum chamber, connected to a vacuum pump and a mass spectrometer. The tiny amount of gas that entered the device under pressure will be released in the vacuum chamber and sent to the mass spectrometer where the leak rate will be measured down to 10−9 mbar·L·s−1. This method is not able to detect a massive leak as the tracer gas will be quickly pumped out when test chamber is pumped down.
The administration of reboxetine with food delayed the absorption rate by approximately 2 hours while not affecting the extent of absorption. The absolute bioavailability is approximately 94%. Plasma concentrations of reboxetine fell in one exponential phase (monoexponential) with a half-life of about 12 hours. Steady-state is seen within 5 days. Reboxetine is 97% protein bound in young people and 92% in the elderly and is distributed into total body water. Radioactivity excreted in the urine corresponds to 78% of the dose. Even though the drug is mainly unchanged in blood circulation (70% of total radioactivity, as the area under the concentration curve (AUC)), only about 10% of the dose is excreted unchanged in the urine. Reboxetine is almost fully metabolised after oral administration. The drug is mainly metabolised through o-dealkylation and oxidation of the morpholine ring and hydroxylation of the ethoxyphenoxy ring. In vitro studies indicate that the CYP450(3A4) enzyme is primarily responsible for the metabolism of reboxetine. The drug is available as a racemic compound. The RR enantiomer is 10 times less potent than the SS enantiomer. The SS enantiomer (more potent) has a plasma level that is two times lower than the urinary excretion. Elimination of reboxetine is mainly via hepatic metabolism (by cytochrome P450 3A4) with a mean terminal half-life of about 12 hours. No significant difference was observed in the terminal half-lives of the RR and SS diastereomers. About 10% of the dose of reboxetine is cleared renally.
Sources: en.wikipedia.org
In May 2000, the GSI successfully repeated the experiment to synthesize a further atom of copernicium-277. This reaction was repeated at RIKEN using the Search for a Super-Heavy Element Using a Gas-Filled Recoil Separator set-up in 2004 and 2013 to synthesize three further atoms and confirm the decay data reported by the GSI team. This reaction had also previously been tried in 1971 at the Joint Institute for Nuclear Research in Dubna, Russia to aim for 276Cn (produced in the 2n channel), but without success. Work had also been done there from 1998 to synthesize the heavier isotope 283Cn in the hot fusion reaction 238U(48Ca,3n)283Cn; most observed atoms of 283Cn decayed by spontaneous fission, although an alpha decay branch to 279Ds was detected. While initial experiments aimed to assign the produced nuclide with its observed long half-life of 3 minutes based on its chemical behaviour, this was found to be not mercury-like as would have been expected (copernicium being under mercury in the periodic table), and indeed now it appears that the long-lived activity might not have been from 283Cn at all, but its electron capture daughter 283Rg instead, with a shorter 4-second half-life associated with 283Cn.
Mast cells are seen as "first responders" that deal with pathogens by alerting other immune cells and coordinating immune responses in the innate and acquired immune systems. When activated, a mast cell can either selectively release (piecemeal degranulation) or rapidly release (anaphylactic degranulation) compounds or mediators from storage granules into the local environment. In addition to the rapid release of pre-formed stored mediators, mast cells can also secrete newly synthesized mediators. The activation of mast cell receptors in specific signaling networks leads to the selective release of mediators that manage both local rapid reactions and long-term responses to stimuli. As part of a healthy immune system, mast cell mediators manage cycles of inflammation and repair, initially producing inflammation to counter harmful stimuli and later repairing damaged tissues to restore homeostasis. MCs play an important protective role in the defense and repair of cells through wound healing, angiogenesis, vascular permeability, and responses to bacteria, parasites, fungi, viruses and venoms. Dysfunction of mast cells is linked to a variety of diseases: MCs are best known for their roles in allergy, anaphylaxis, and eczema (atopic dermatitis).
Homocysteine (symbol Hcy) is a non-proteinogenic α-amino acid. It is a homologue of the amino acid cysteine, differing by an additional methylene bridge (−CH2−). It is biosynthesized from methionine by the removal of its terminal Cε methyl group. Although the production of homocysteine is a normal part of the metabolism of methionine, an excess of homocysteine can be harmful. There are two primary ways for organisms such as humans to metabolize homocysteine: remethylation and transsulfuration. Remethylation adds a methyl group to the homocysteine molecule, converting homocysteine back into methionine. There are two known remethylation pathways. One pathway requires vitamin B9 (folate) and B12 (cobalamin), which drive the MTR (methionine synthase) and MTRR (methionine synthase reductase) enzymes. The other pathway uses TMG (trimethylglycine) to drive the BHMT (betaine-homocysteine methyltransferase) enzyme. Transsulfuration converts homocysteine to cystathionine. This pathway requires vitamin B6 to drive the CBS (cystathionine beta synthase) enzyme. Cystathionine is the immediate precursor of the amino acid cysteine, which (along with glutamate and glycine), is incorporated into the tripeptide glutathione, a major antioxidant in the human body. Homocysteine is therefore an important metabolic substrate. However, excessive levels of homocysteine can result in hyperhomocysteinemia, which is regarded as an indicator of cardiovascular disease risk. Homocysteine likely contributes to atherogenesis, which can result in ischemic injury.
=== Federal dissolution; the roots of mistrust === Meanwhile, secessionist black Rhodesian parties won electoral victories in Northern Rhodesia and Nyasaland, and Harold Macmillan's Conservative administration in Britain moved towards breaking up the Federation, resolving that it had become untenable. In February 1962, the British Secretary of State for Commonwealth Relations, Duncan Sandys, secretly informed the Nyasaland nationalist leader Hastings Banda that secession would be allowed. A few days later, he horrified Welensky by telling him that "we British have lost the will to govern". "But we haven't", retorted Julian Greenfield, Welensky's Law Minister. Macmillan's Deputy Prime Minister and First Secretary of State, R. A. Butler, who headed British oversight of the Federation, officially announced Nyasaland's right to secede in December 1962. Four months later, he informed the three territories that he was going to convene a conference to decide the Federation's future. As Southern Rhodesia had been the UK's legislative partner in forming the Federation in 1953, it would be impossible (or at least very difficult) for Britain to dissolve the union without Southern Rhodesia's co-operation. Field could therefore potentially hamstring the British by refusing to attend the conference until they pledged to grant his country full independence. According to Field, Smith and other RF politicians, Butler made several such guarantees orally to ensure their co-operation at the conference, but repeatedly refused to give anything on paper.
Furthermore, several newer studies have documented the substantial benefits of cold exposure in multiple species including humans, for example researchers concluded that "activation of brown adipose tissue is a powerful therapeutic avenue to ameliorate hyperlipidaemia and protect from atherosclerosis" and that brown fat activation reduces plasma triglyceride and cholesterol levels and attenuates diet-induced atherosclerosis development. Long-term studies of adult humans are needed to establish a balance of benefit and risk, in combination with historical research of living conditions of recent human generations prior to the current increase of poor health related to excessive accumulation of white fat. Pharmacological approaches using β3-adrenoceptor agonists have been shown to enhance glucose metabolic activity of brown adipose tissue in rodents. Additionally research has shown:
Sources: en.wikipedia.org
This process can also be further adjusted by manipulating factors such as pH, temperature, exudate dilution and plant origin to produce different shapes of nanoparticles, including triangles, spheres, rods, and spirals. These biogenic metallic nanoparticles then have applications as catalysts, glass window coatings to insulate heat, in biomedicine, and in biosensor devices.
This delivery method gained worldwide recognition during COVID-19 pandemic with the approval of mRNA vaccines from Pfizer-BioTech and Moderna. The rapid rollout of these vaccines proved that LNPs are not only effective but also scalable for mass production and global use. Looking beyond vaccines, mRNA therapies are now being explored for a range of therapeutic applications including cancer immunotherapy, genetic disorders, and other infectious diseases. Researchers are also testing alternative delivery systems, like exosomes and new types of nanoparticles, to make mRNA therapies safer and more efficient. However, challenges remain, as mRNA is highly sensitive to environmental conditions. To address this, ongoing research is expanding into new administration routes including inhalable or oral mNRA formulations. This could reduce production costs and make these therapies more accessible to the world.
=== France === In France, a clinical biologist (biologiste médical) is a doctor in medicine or pharmacy who has completed a four-year specialization in medical biology. The profession is strictly regulated, and clinical biologists are responsible for overseeing and interpreting laboratory analyses. Their training includes a national competitive exam (internat de biologie médicale), followed by a structured residency program in clinical laboratories. They play a key role in laboratory diagnostics, clinical decision-making, and quality management of biological analyses.
== Role of protein synthesis in disease == Many diseases are caused by mutations in genes, due to the direct connection between the DNA nucleotide sequence and the amino acid sequence of the encoded protein. Changes to the primary structure of the protein can result in the protein mis-folding or malfunctioning. Mutations within a single gene have been identified as a cause of multiple diseases, including sickle cell disease, known as single gene disorders.
=== Lithium-air battery === Among many advanced electrochemical energy storage devices, rechargeable lithium-air batteries are of particular interest due to their considerable energy storing capacities and high power densities. As the battery is being used, lithium ions combine with oxygen from the air to form particles of lithium oxides, which attach to carbon fibers on the electrode. During recharging, the lithium oxides separate again into lithium and oxygen which is released back into the atmosphere. This conversion sequence is highly inefficient because there is significant voltage difference of more than 1.2 volts between the output voltage and the charging voltage of the battery meaning that approximately 30% of the electrical energy is lost as heat when the battery is charging. Also the large volume changes resulting from continuous conversion of oxygen between its gaseous and solid state puts stress on the electrode and limits its lifetime.
Sources: en.wikipedia.org
It has not been approved as a therapeutic by major regulators, and the human trial record is small and dated. Material available today is mostly sold as a research chemical for laboratory use. Approval and restriction status varies by country.
It binds the ghrelin receptor, known as the growth hormone secretagogue receptor type 1a. Activation of that receptor triggers signaling that leads to growth hormone release. Selectivity for growth hormone over cortisol and prolactin is the property most often cited for this compound.
Published estimates place the circulating half-life at roughly two hours in humans. Clearance involves peptidase activity and renal handling. Because the peptide is short-lived, release patterns after administration are usually described as pulsatile rather than sustained.
不是。它属于人工合成的五肽，设计上模拟胃饥饿素受体的部分作用，但不存在于人体天然激素谱中。